Using Real-World Lab Data Insights to Improve Biomarker Testing in Lung Cancer

As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted therapies for this patient population.

Professional organizations such as the National Comprehensive Cancer Network (NCCN) have adeptly remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.

In this lite paper, we take a critical look at lung cancer biomarker testing rates in the community practice setting and how they compare with NCCN guidelines utilizing data insights from the largest oncology testing database in the US.

Here, you’ll learn:

  • How often lung cancer patients in the community setting are being tested for all nine actionable NCCN-recommended biomarkers
  • The implications of current testing algorithms on time to treatment and tissue availability
  • How real-world lab data provides evidence-based rationale for building precision oncology programs

Download

 

To learn more about how real-world insights from NeoGenomics can support your precision oncology programs visit NeoEngage

Lite paper background: As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted therapies for this patient population. Professional organizations such as the National Comprehensive Cancer Network (NCCN) have adeptly remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.

Co-authors: 
Dr. Derek Lyle, Chief Medical Officer NeoGenomics Clinical Services 
Kate Clark, Head of Client Engagement NeoGenomics Informatics

Written By:
DerekLyle.jpeg
Derek Lyle, MD
Chief Medical Officer

Dr. Lyle joined NeoGenomics in 2018. Before joining NeoGenomics, Dr. Lyle worked at Genoptix Medical Laboratory for 9 years, where he initially served as Director of Hematopathology and, later, as Medical Director and Chief Medical Officer. Prior to joining Genoptix, Dr. Lyle worked as a surgical pathologist in Palm Springs, CA. Dr. Lyle completed combined Anatomic Pathology and Clinical Pathology residency training at Cedars-Sinai Medical Center in Los Angeles, CA, where he served as Chief Resident, and a Hematopathology fellowship at City of Hope National Medical Center. He is board-certified in Anatomic Pathology, Clinical Pathology, and Hematopathology.

The content in the blogs herein relate to the opinions and views expressed by the individual blog author(s) and contributors and are not necessarily the viewpoints held by NeoGenomics Inc., or any of its affiliates or entities.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients

Learn More